Telix Pharmaceuticals Limited, a commercial-stage biopharmaceutical company, focuses on the development and commercialization of therapeutic and diagnostic radiopharmaceuticals.
The company operates through three segments: Precision Medicine, Therapeutics, and Manufacturing Solutions.
Its lead therapeutic product candidate is TLX591, a lutetium-labeled radio antibody-drug conjugate (rADC), which is in a Phase 3 clinical trial in patients with advanced prostate cancer.
The company develops TLX250, an rADC for treating advanced metastatic kidney cancer; TLX101, a systemic therapy for the treatment of glioblastoma; TLX66, a product candidate for bone marrow conditioning for hematopoietic stem cell transplant conditioning; and Illuccix and Gozellix for the treatment of prostate cancer.
The company is also developing TLX592, a prostate cancer therapy candidate for targeted alpha therapy based on its proprietary RADmAb-engineered antibody technology; TLX252 for the treatment of patients with advanced metastatic kidney cancer; TLX400, a bladder fibroblast activation protein for treating various tumors; TLX102, a large amino acid transporter-targeting small molecule-based alpha therapy candidate for the treatment of glioblastoma and multiple myeloma; TLX300 for treating soft tissue sarcoma; and TLX090, a bone-seeking agent for bone metastases and pain palliation.
In addition, it is developing TLX250-CDx, a positron emission tomography (PET) diagnostic imaging agent for the characterization of renal masses as clear cell renal cell carcinoma; TLX101-CDx, a PET diagnostic agent to image cancerous lesions in the brain; and TLX66-CDx, a cluster of differentiation 66 imaging agent for osteomyelitis (bone infection).
It operates in Australia, Belgium, Canada, the United Kingdom, the United States, and internationally.
The company was founded in 2015 and is headquartered in North Melbourne, Australia.
| Reported date | EPSChange YoY | EstimateSurprise |
|---|---|---|
| Apr 22, 25 | 0.09 | - |
| Feb 20, 25 | 0.06 | - |
| Oct 17, 24 | 0.00 | - |
| Fiscal ending date | RevenueChange YoY | IncomeChange YoY | ProfitChange YoY |
|---|---|---|---|
| Dec 31, 24 | 594.24 M Increased by +7.92 K% | 38.24 M Increased by +2.52 K% | Increased by +6.43% Increased by +130.16% |
| Jun 30, 24 | 188.96 M Increased by +2.76 K% | 11.68 M Increased by +9.53 K% | Increased by +6.18% Increased by +237.10% |
| Dec 31, 23 | 281.71 M Increased by +5.16 K% | 19.53 M Increased by +8.88 K% | Increased by +6.93% Increased by +70.91% |
| Jun 30, 23 | 220.83 M Increased by +4.26 K% | -14.32 M Decreased by -1.84 K% | Decreased by -6.48% Increased by +55.38% |
| Dec 31, 19 | 7.41 M Increased by +55.17% | -1.58 M Increased by +64.94% | Decreased by -21.33% Increased by +77.41% |
| Sep 30, 19 | 6.61 M Increased by +59.02% | 121.25 K Increased by +107.17% | Increased by +1.83% Increased by +104.51% |
| Jun 30, 19 | 5.36 M Decreased by -9.29% | 217.40 K Increased by +222.70% | Increased by +4.06% Increased by +235.27% |
| Mar 31, 19 | 5.07 M Decreased by -72.37% | -736.76 K Increased by +85.77% | Decreased by -14.53% Increased by +48.49% |